Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Mucormycosis (previously called as zygomycosis) is a serious but rare fungal infection caused by a group of molds called mucormycetes. Moreover, inhaling fungal spores from the air can affect the lungs and sinuses. The fungus also invades the skin through wounds such as cut, scrape, burn, or other type of skin trauma. Fungal infection may affect anyone, but they are most common in people with weakened immune systems and can occur in nearly any part of the body. Risk factors for developing mucormycosis include uncontrolled diabetes, cancer, organ transplant, neutropenia, skin trauma.  Mucormycosis needs to be treated with prescribed antifungal medication such as amphotericin B, posaconazole or isavuconazole. Amphotericin B, posaconazole, and isavuconazole are medications given intravenously. Furthermore, posaconazole and isavuconazole can also be administered orally.

India Mucormycosis Treatment (Black Fungus Drugs) Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic is expected to drive growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecast period, owing to increasing cases of mucormycosis infection in the COVID-19 positive or in patients who have recovered from COVID-19 infection. For instance, according to the article published in the Diabetes and Metabolic Syndrome Journal: May 21, 2021, COVID-19 infection has been associated with a wide range of bacterial and fungal infections. Currently, mucormycosis infection cases are rising in the Indian population due to the presence of ideal environment in the COVID-19 patients, low oxygen, high glucose (in case of diabetes or steroid induces hyperglycemia), acidic medium (diabetic ketoacidosis and others), high iron levels, and suppressed immune system along with other comorbidities.

DOs DON’TS
To control hyperglycemia Do not miss warning signs and symptoms
To monitor blood glucose level post COVID-19 discharge and also in diabetics Do not ignore and consider that the cases with blocked nose as cases of bacterial sinusitis, particularly in patients with immunosuppression and/or COVID-19 patients on immunomodulators
To use steroid properly Do not self-medicate and seek investigations (KOH staining & microscopy, culture, MALDITOF) for detecting fungal infection
To use clean, sterile water for humidifiers during oxygen therapy Do not lose crucial time to initiate treatment for mucormycosis
To use antibiotics/antifungals with care  

Government authorities are spreading awareness for the early detection and management of mucormycosis in the COVID-19 patients. For instance, Indian Council of Medical Research (ICMR), released guidelines i.e., Dos and Don’ts for the COVID – 19 patients.

request-sample

India Mucormycosis Treatment (Black Fungus Drugs) Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 9.1 Mn
Historical Data for: 2018 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 3.5% 2027 Value Projection: US$ 11.7 Mn
Geographies covered:
  • India
Segments covered:
  • By Drugs: Amphotericin B, Isavuconazole, Posaconazole, Voriconazole, Flucytosine, Fluconazole, Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Natco Pharmaceuticals, Alembic Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, Emcure Pharmaceuticals, Bharat Serums and Vaccines, BDR Pharmaceuticals, Cipla Limited, Lifecare Innovations, Synbiotics Limited, Kamla Lifesciences, Cadila Healthcare Limited, and TLC Pharma Labs

Growth Drivers:
  • Increasing collaboration among the market players
  • Increasing prevalence of mucormycosis
  • Increasing allotment of license to the manufacturers for production of Amphotericin B
  • Increasing government initiatives for increasing availability of drugs for the treatment of mucormycosis 
Restraints & Challenges:
  • High cost of the treatment of mucormycosis
  • Drug shortages 

India Mucormycosis Treatment (Black Fungus Drugs) market is estimated to be valued at US$ 9.1 Mn in 2021 and is expected to exhibit a CAGR of 3.5% over the forecast period (2021-2028).

 Figure 1: India Mucormycosis Treatment (Black Fungus Drugs) Market Share (%) Analysis, By Species, 2021

India Mucormycosis Treatment (Black Fungus Drugs)  | Coherent Market Insights

Market Players are engaged in receiving license from the Indian government, in order to manufacture Amphotericin – B, an anti-fungal drug for the treatment of Black Fungus or mucormycosis. This is expected to drive growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecast period.

Indian government has provided license to some of the market players, in order to manufacture anti-fungal drug, Amphotericin – B for the treatment of Mucormycosis (Black Fungus Drugs). For instance, on May 22, 2021, Indian government gave license to five manufacturers: Emcure Pharmaceuticals, Natco Pharmaceuticals, Gufic Biosciences, Alembic Pharmaceuticals, and Lyca Pharmaceuticals. These companies will start producing 111,000 vials of Amphotericin – B each month from July 2021.

Key players are engaged in entering into an agreement, in order to manufacture anti- fungal drugs for black fungus. This is expected to drive growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecast period.

The increasing agreements by the market players for the manufacture of anti-fungal drug in the treatment of mucormycosis is expected to drive growth of the market over the forecast period. For instance, on May 26, 2021, Cadila Healthcare Limited and TLC Pharma Labs, entered into an agreement to manufacture anti-fungal drug ‘Liposomal Amphotericin B’ for the treatment of mucormycosis or black fungus in India.

Increasing prevalence of mucormycosis in the Indian population with comorbidities is expected to drive growth of the India Mucormycosis Treatment (Black Fungus Drugs) market

In India, diabetes mellitus is the most common underlying disease. For instance, according to the article published in the Microorganism Journal, on March 4, 2021, the pie chart shows the percentage of mucormycosis burden in different at-risk populations in India. According to the same source, diabetes mellitus is a common predisposing factor for the rhino-orbital-cerebral mucormycosis (ROCM) type of disease. A recent study from India reported that 77% of ROCM cases were in the diabetic population.

India Mucormycosis Treatment (Black Fungus Drugs)  | Coherent Market Insights

Moreover, according to the article published by the Indian Ministry of Chemicals and Fertilizers, around 8,848 cases of mucormycosis has been reported till May 25, 2021 in India. The following graph shows the number of cases of mucormycosis infection reported in each state in India, till May 25, 2021.

India Mucormycosis Treatment (Black Fungus Drugs)  | Coherent Market Insights

India Mucormycosis Treatment (Black Fungus Drugs) Market – Restraints

High cost of the medicines for the treatment of mucormycosis is expected to restrain growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecast period. For instance, the only antifungal drug, Amphotericin B is expensive and it will be difficult for the people to bear the cost. Currently the single vial of the drug is available in the market at a price of US$ 68.6 to US$ 109.9 (5,000 to 8,000 Indian rupees). Moreover the medicines have to be taken for 4 to 12 weeks, thus, many patients fail to take the treatment due to high cost. Government intervention may help in curbing the cost of the medicines.

Furthermore, drug shortages is another factor, which may hamper growth of the market. For instance, Kerala, a state in South India, declared Amphotericin B shortage in the market. Moreover, on an average a mucormycosis patient requires 100 vials of Amphotericin B for their treatment. Thus, India will require 9 to 10 lakhs injections of Amphotericin B for 9,000 mucormycosis patients. Thus, the above factors are expected to restrain the growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecast period.

Figure 2: India Mucormycosis Treatment (Black Fungus Drugs) Market Value (US$ Mn) & Y-o-Y Growth (%), 2020 - 2028

India Mucormycosis Treatment (Black Fungus Drugs)  | Coherent Market Insights

India Mucormycosis Treatment (Black Fungus Drugs) Market – Competitive Landscape

Major players operating in the India Mucormycosis Treatment (Black Fungus Drugs) market include Natco Pharmaceuticals, Alembic Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, Emcure Pharmaceuticals, Bharat Serums and Vaccines, BDR Pharmaceuticals, Cipla Limited, Lifecare Innovations, Synbiotics Limited, Kamla Lifesciences, Cadila Healthcare Limited, and TLC Pharma Labs

Mucormycosis is a rapidly progressive and life-threatening invasive fungal disease with high morbidity and mortality rates despite treatment. It primarily affects immunocompromised patients such as those with organ and bone marrow transplantation, hematological malignancy, and patients with diabetes, cancer, neutropenia, and skin trauma. In rare cases it also affects immunocompetent patients. Mucormycosis is caused by a group of molds called mucormycetes. Inhaling the spores of the molds can affect the lungs and sinuses, and the fungus may also invade the skin through wounds such as cuts, burns, scrapes, or other types of skin trauma.

Market Dynamics

Major players in the market are indulged in inorganic activities such as collaborations with other market players, in order to launch anti-fungal drugs for the treatment of mucormycosis in the Indian population. This is expected to fuel growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecast period. For instance, on May 27, 2021, Strides Pharma Science Limited, a pharmaceutical company headquartered in Bangalore, India, are collaborating with TLC Pharma, a pharmaceutical company headquartered in Telangana, India, for launching TLC Pharma’s product AmphoTLC, a liposomal amphotericin B injection indicated for the treatment of various systemic fungal infections such as mucormycosis.

Different fungal species are involved for causing mucormycosis infection in Indian population. According to the article published in the Microorganism Journal, on March 4, 2021, the following graph shows the contribution of different species to mucormycosis burden in India (in percentage)

Key features of the study:

  • This report provides an in-depth analysis of India Mucormycosis Treatment (Black Fungus Drugs) market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the India Mucormycosis Treatment (Black Fungus Drugs) market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Natco Pharmaceuticals, Alembic Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, Emcure Pharmaceuticals, Bharat Serums and Vaccines, BDR Pharmaceuticals, Cipla Limited, Lifecare Innovations, Synbiotics Limited, Kamla Lifesciences, Cadila Healthcare Limited, and TLC Pharma Labs
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The India Mucormycosis Treatment (Black Fungus Drugs) market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the India Mucormycosis Treatment (Black Fungus Drugs) market

Detailed Segmentation:

  • India Mucormycosis Treatment (Black Fungus Drugs) Market, By Drugs:
    • Amphotericin B
    • Isavuconazole
    • Posaconazole
    • Voriconazole
    • Flucytosine
    • Fluconazole
    • Others
  • India Mucormycosis Treatment (Black Fungus Drugs) Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • Natco Pharmaceuticals *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Alembic Pharmaceuticals
    • Gufic Biosciences
    • Lyca Pharmaceuticals
    • Emcure Pharmaceuticals
    • Bharat Serums and Vaccines
    • BDR Pharmaceuticals
    • Cipla Limited
    • Lifecare Innovations
    • Synbiotics Limited
    • Kamla Lifesciences
    • Cadila Healthcare Limited
    • TLC Pharma Labs

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drugs
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Regulatory Scenario
    • PEST Analysis
    • Recent Product Launch/Approval
    • Epidemiology
    • Diagnosis and Treatment Overview
    • Competitive Intelligence
    • Prescription Pattern
    • Physicians Preferences and Views
  4.  India Mucormycosis Treatment (Black Fungus Drugs) Market - Impact of Coronavirus (Covid-19) Pandemic
    • Impact on Supply Chain
    • Impact on Diagnosis and Treatment
    • Impact on Research and Development
  5. India Mucormycosis Treatment (Black Fungus Drugs) Market, By Drugs 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 - 2028
      • Segment Trends
    • Amphotericin B
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Isavuconazole
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Posaconazole
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Voriconazole
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Flucytosine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Fluconazole
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  6. India Mucormycosis Treatment (Black Fungus Drugs) Market, By Distribution Channel, 2017 - 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2017 - 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  7. Competitive Landscape
    • Company Profiles
      • Natco Pharmaceuticals
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Alembic Pharmaceuticals
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Gufic Biosciences
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Lyca Pharmaceuticals
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Emcure Pharmaceuticals
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Bharat Serums and Vaccines
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • BDR Pharmaceuticals
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Cipla Limited
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Lifecare Innovations
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Synbiotics Limited
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Kamla Lifesciences
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Cadila Healthcare Limited
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • TLC Pharma Labs
        • Company Overview
        • Drug Type Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 32 market data tables and 26 figures on "India Mucormycosis Treatment (Black Fungus Drugs) Market” - India Forecast to 2028.

FAQgrowicon

Frequently Asked Questions

The India Mucormycosis Treatment (Black Fungus Drugs) Market is expected to exhibit a CAGR of 3.5% during the forecast period (2021-2028).
The market is estimated to be valued at US$ 9.1 Mn in 2021.
Natco Pharmaceuticals, Alembic Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, Emcure Pharmaceuticals, Bharat Serums and Vaccines, BDR Pharmaceuticals, Cipla Limited, Lifecare Innovations, Synbiotics Limited, Kamla Lifesciences, Cadila Healthcare Limited, and TLC Pharma Labs are some of the prominent players operating in the market over the forecast period.
The market is expected to be valued at US$ 9.1 Mn in 2028.
Amphotericin B segment is expected to hold a major share in 2028 in the treatment.
Increasing collaboration among the market players, increasing prevalence of mucormycosis, increasing allotment of license to the manufacturers for production of Amphotericin B, and increasing government initiatives for increasing availability of drugs for the treatment of mucormycosis are some of the driving factors for the market growth.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.